Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Digital do Instituto Evandro Chagas (Patuá) |
Texto Completo: | https://patua.iec.gov.br/handle/iec/946 |
Resumo: | Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls. |
id |
IEC-2_67b68cdada1abff8657d738841ab3c7e |
---|---|
oai_identifier_str |
oai:patua.iec.gov.br:iec/946 |
network_acronym_str |
IEC-2 |
network_name_str |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
repository_id_str |
|
spelling |
Justino, Maria Cleonice AguiarLinhares, Alexandre da CostaLanzieri, Tatiana. MMiranda, YlleMascarenhas, Joana D'Arc PereiraAbreu, ErikaGuerra, Sylvia de Fátima dos SantosOliveira, Alessilva S. LSilva, Veronice B. daSanchez, NervoMeyer, NadiaShafi, FakrudeenOrtega-Barria, EduardoSoriano-Gabarró, MontseColindres, Romulo E2016-01-26T11:39:50Z2016-01-26T11:39:50Z2011JUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011. DOI: https://doi.org/10.1097/INF.0b013e3182055cc2.1871-0336https://patua.iec.gov.br/handle/iec/94610.1097/INF.0b013e3182055cc2Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.GlaxoSmithKline. Rio de Janeiro, RJ, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.GlaxoSmithKline. Rio de Janeiro, RJ, Brasil.GlaxoSmithKline Biologicals. Wavre, Belgium.GlaxoSmithKline Biologicals. Bangalore, India.GlaxoSmithKline. Rio de Janeiro, RJ, Brasil.GlaxoSmithKline Biologicals, Wavre, Belgium.GlaxoSmithKline. Rio de Janeiro, RJ, Brasilapplication/pdfengLippincott, Williams & WilkinsEffectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article20082009Gastroenterite / virologiaRotavirus / isolamento & purificaçãoVacinas contra RotavirusHospitalizaçãoinfo:eu-repo/semantics/embargoedAccessreponame:Repositório Digital do Instituto Evandro Chagas (Patuá)instname:Instituto Evandro Chagas (IEC)instacron:IECTEXTfile_1.pdf.txtfile_1.pdf.txtExtracted texttext/plain39133https://patua.iec.gov.br/bitstreams/f67cca24-1d20-462c-9751-5f7b70e1e4cb/downloadb4a728b35026c7be44f04c20fd8e113bMD52Effectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.txtEffectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.txtExtracted texttext/plain39133https://patua.iec.gov.br/bitstreams/0dcb8f4b-7333-47a4-9ca1-2e75bd1902b7/downloadb4a728b35026c7be44f04c20fd8e113bMD53Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.txtEffectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.txtExtracted texttext/plain39133https://patua.iec.gov.br/bitstreams/98ac4a4d-20c7-4832-9498-6325a362efa9/downloadb4a728b35026c7be44f04c20fd8e113bMD55Acesso Embargado.pdf.txtAcesso Embargado.pdf.txtExtracted texttext/plain2https://patua.iec.gov.br/bitstreams/b3b14f19-ba3c-41f1-a0a8-ef28fd417ccd/downloade1c06d85ae7b8b032bef47e42e4c08f9MD511THUMBNAILEffectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.jpgEffectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.jpgIM Thumbnailimage/jpeg5333https://patua.iec.gov.br/bitstreams/f72dc534-f82d-4f1b-a92b-a4e67d107297/download45ce6e12ef4e729cfe9475020205fe2fMD54Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.jpgEffectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.jpgGenerated Thumbnailimage/jpeg1763https://patua.iec.gov.br/bitstreams/3a566108-0153-4295-b811-97d15d644748/download5b11fe0a61e28487f10cb9b29605b388MD56Acesso Embargado.pdf.jpgAcesso Embargado.pdf.jpgGenerated Thumbnailimage/jpeg3095https://patua.iec.gov.br/bitstreams/cd7006d8-5f36-4a95-9515-b88351b638a6/download71859d578212107f7f8c49a4ce09d9eeMD512ORIGINALAcesso Embargado.pdfAcesso Embargado.pdfapplication/pdf551083https://patua.iec.gov.br/bitstreams/bd078aab-ce17-4f7a-ae40-a3acc2ccbe79/downloadc9a9c128e29cac82a5d7fdf3f4e6da73MD57LICENSElicense.txtlicense.txttext/plain; charset=utf-82182https://patua.iec.gov.br/bitstreams/13470106-fb99-4821-acab-52cc99ecc50a/download11832eea31b16df8613079d742d61793MD510iec/9462022-10-20 21:34:04.505oai:patua.iec.gov.br:iec/946https://patua.iec.gov.brRepositório InstitucionalPUBhttps://patua.iec.gov.br/oai/requestclariceneta@iec.gov.br || Biblioteca@iec.gov.bropendoar:2022-10-20T21:34:04Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)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 |
dc.title.pt_BR.fl_str_mv |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
title |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
spellingShingle |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil Justino, Maria Cleonice Aguiar Gastroenterite / virologia Rotavirus / isolamento & purificação Vacinas contra Rotavirus Hospitalização |
title_short |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
title_full |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
title_fullStr |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
title_full_unstemmed |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
title_sort |
Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil |
author |
Justino, Maria Cleonice Aguiar |
author_facet |
Justino, Maria Cleonice Aguiar Linhares, Alexandre da Costa Lanzieri, Tatiana. M Miranda, Ylle Mascarenhas, Joana D'Arc Pereira Abreu, Erika Guerra, Sylvia de Fátima dos Santos Oliveira, Alessilva S. L Silva, Veronice B. da Sanchez, Nervo Meyer, Nadia Shafi, Fakrudeen Ortega-Barria, Eduardo Soriano-Gabarró, Montse Colindres, Romulo E |
author_role |
author |
author2 |
Linhares, Alexandre da Costa Lanzieri, Tatiana. M Miranda, Ylle Mascarenhas, Joana D'Arc Pereira Abreu, Erika Guerra, Sylvia de Fátima dos Santos Oliveira, Alessilva S. L Silva, Veronice B. da Sanchez, Nervo Meyer, Nadia Shafi, Fakrudeen Ortega-Barria, Eduardo Soriano-Gabarró, Montse Colindres, Romulo E |
author2_role |
author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Justino, Maria Cleonice Aguiar Linhares, Alexandre da Costa Lanzieri, Tatiana. M Miranda, Ylle Mascarenhas, Joana D'Arc Pereira Abreu, Erika Guerra, Sylvia de Fátima dos Santos Oliveira, Alessilva S. L Silva, Veronice B. da Sanchez, Nervo Meyer, Nadia Shafi, Fakrudeen Ortega-Barria, Eduardo Soriano-Gabarró, Montse Colindres, Romulo E |
dc.subject.decsPrimary.pt_BR.fl_str_mv |
Gastroenterite / virologia Rotavirus / isolamento & purificação Vacinas contra Rotavirus Hospitalização |
topic |
Gastroenterite / virologia Rotavirus / isolamento & purificação Vacinas contra Rotavirus Hospitalização |
description |
Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls. |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011 |
dc.date.accessioned.fl_str_mv |
2016-01-26T11:39:50Z |
dc.date.available.fl_str_mv |
2016-01-26T11:39:50Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
JUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011. DOI: https://doi.org/10.1097/INF.0b013e3182055cc2. |
dc.identifier.uri.fl_str_mv |
https://patua.iec.gov.br/handle/iec/946 |
dc.identifier.issn.-.fl_str_mv |
1871-0336 |
dc.identifier.doi.pt_BR.fl_str_mv |
10.1097/INF.0b013e3182055cc2 |
identifier_str_mv |
JUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011. DOI: https://doi.org/10.1097/INF.0b013e3182055cc2. 1871-0336 10.1097/INF.0b013e3182055cc2 |
url |
https://patua.iec.gov.br/handle/iec/946 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.coverage.temporalragefrom.-.fl_str_mv |
2008 |
dc.coverage.temporalrageupto.-.fl_str_mv |
2009 |
dc.publisher.none.fl_str_mv |
Lippincott, Williams & Wilkins |
publisher.none.fl_str_mv |
Lippincott, Williams & Wilkins |
dc.source.none.fl_str_mv |
reponame:Repositório Digital do Instituto Evandro Chagas (Patuá) instname:Instituto Evandro Chagas (IEC) instacron:IEC |
instname_str |
Instituto Evandro Chagas (IEC) |
instacron_str |
IEC |
institution |
IEC |
reponame_str |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
collection |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
bitstream.url.fl_str_mv |
https://patua.iec.gov.br/bitstreams/f67cca24-1d20-462c-9751-5f7b70e1e4cb/download https://patua.iec.gov.br/bitstreams/0dcb8f4b-7333-47a4-9ca1-2e75bd1902b7/download https://patua.iec.gov.br/bitstreams/98ac4a4d-20c7-4832-9498-6325a362efa9/download https://patua.iec.gov.br/bitstreams/b3b14f19-ba3c-41f1-a0a8-ef28fd417ccd/download https://patua.iec.gov.br/bitstreams/f72dc534-f82d-4f1b-a92b-a4e67d107297/download https://patua.iec.gov.br/bitstreams/3a566108-0153-4295-b811-97d15d644748/download https://patua.iec.gov.br/bitstreams/cd7006d8-5f36-4a95-9515-b88351b638a6/download https://patua.iec.gov.br/bitstreams/bd078aab-ce17-4f7a-ae40-a3acc2ccbe79/download https://patua.iec.gov.br/bitstreams/13470106-fb99-4821-acab-52cc99ecc50a/download |
bitstream.checksum.fl_str_mv |
b4a728b35026c7be44f04c20fd8e113b b4a728b35026c7be44f04c20fd8e113b b4a728b35026c7be44f04c20fd8e113b e1c06d85ae7b8b032bef47e42e4c08f9 45ce6e12ef4e729cfe9475020205fe2f 5b11fe0a61e28487f10cb9b29605b388 71859d578212107f7f8c49a4ce09d9ee c9a9c128e29cac82a5d7fdf3f4e6da73 11832eea31b16df8613079d742d61793 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC) |
repository.mail.fl_str_mv |
clariceneta@iec.gov.br || Biblioteca@iec.gov.br |
_version_ |
1809190040232787968 |